Analyst Profile

Followed by 270 followers
.
Graig Suvannavejh

Graig Suvannavejh

Mizuho Securities
Wall Street Analyst
#3,037 out of 8,087 Wall Street Analysts
#6,948 out of 24,283 experts

Success Rate

52%
64 out of 122 transactions made a profit

Average Return

+2.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Graig Suvannavejh's trades since 2012 and holding each position for 1 Year would result in 52.46% of your transactions generating a profit, with an average return of 2.4% per rating.

Stock Rating Distribution

231Ratings
56.71% Buy
38.96% Hold
4.33% Sell
Distribution of Graig Suvannavejh's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market
GermanyGermany Market

Best Rating

Stock:
Halozyme Therapeutics
(HALO)
Rating:Buy
Date:Jan 08, 2020 - Jan 08, 2021
Return:+136.10%
The most profitable rating made by Graig Suvannavejh

Graig Suvannavejh's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Alkermes
Mar 22, 2012
Buy
Reiterated
$24.00
(-4.00% Downside)
3Ratings
100%
+32.80%
Fortress Biotech
Oct 15, 2013
Hold
Downgraded
$2.00
(200.89% Upside)
3Ratings
0%
-82.30%
Oramed Pharmaceuticals
Feb 03, 2014
Buy
Reiterated
$27.00
(226.48% Upside)
2Ratings
0%
-75.75%
Ligand Pharma
Feb 13, 2014
Buy
Reiterated
$96.00
(41.53% Upside)
2Ratings
50%
-8.50%
Lumos Pharma
Mar 31, 2014
Buy
Reiterated
$45.00
(831.68% Upside)
4Ratings
100%
+38.78%
Alterity Therapeutics
Apr 01, 2014
Hold
Downgraded
$3.00
(766.55% Upside)
1Ratings
0.00%
Xoma
Apr 29, 2014
Buy
Upgraded
$7.00
(-64.08% Downside)
3Ratings
50%
+0.15%
EyePoint Pharmaceuticals
May 05, 2014
Buy
Initiated
$6.00
(91.08% Upside)
1Ratings
100%
+3.00%
KERX
Keryx Biopharma
May 12, 2014
Buy
Reiterated
1Ratings
0%
-19.20%
Acura Pharmaceuticals
May 28, 2014
Hold
Downgraded
$1.00
(1900.00% Upside)
4Ratings
0%
-28.23%
List of latest recommendations made by Graig Suvannavejh. Click to expand and see Graig Suvannavejh's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >